Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019063551) OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/063551 International Application No.: PCT/EP2018/075974
Publication Date: 04.04.2019 International Filing Date: 25.09.2018
IPC:
A61K 9/00 (2006.01) ,A61K 9/08 (2006.01) ,A61K 47/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
08
Solutions
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
Applicants:
NOVALIQ GMBH [DE/DE]; Im Neuenheimer Feld 515 69120 Heidelberg, DE
Inventors:
GÜNTHER, Bernhard; DE
LÖSCHER, Frank; DE
EICKHOFF, Kirsten; DE
Agent:
PHARMA CONCEPTS GMBH; Unterer Rheinweg 50 4057 Basel, CH
Priority Data:
17193364.127.09.2017EP
Title (EN) OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES
(FR) COMPOSITIONS OPHTALMIQUES COMPRENANT DU LATANOPROST, DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE MALADIES OCULAIRES
Abstract:
(EN) The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein - the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and - the composition is administered to the eye of a subject; and - the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 µg.
(FR) L'invention concerne une composition pharmaceutique destinée à être utilisée dans la prévention ou le traitement du glaucome, d'une augmentation de la pression intraoculaire, d'une hypertension oculaire et/ou d'un symptôme associé à ces derniers, la composition comprenant du latanoprost et un véhicule liquide comprenant un alcane semi-fluoré ; la composition étant administrée au niveau de l’œil d'un patient ; et la quantité de latanoprost administrée en une seule dose par œil se situant dans une plage comprise environ entre 0,5 et 1,4 µg.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)